THK Co., Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Last week, you might have seen that THK Co., Ltd. (TSE:6481) released its quarterly result to the market. The early response was not positive, with shares down 4.2% to JP¥3,961 in the past week. Statutory earnings per share fell badly short of expectations, coming in at JP¥13.66, some 67% below analyst forecasts, although revenues were okay, approximately in line with analyst estimates at JP¥92b. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Following the latest results, THK's 13 analysts are now forecasting revenues of JP¥381.8b in 2026. This would be a credible 7.3% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to leap 227% to JP¥190. Yet prior to the latest earnings, the analysts had been anticipated revenues of JP¥378.4b and earnings per share (EPS) of JP¥197 in 2026. So it looks like there's been a small decline in overall sentiment after the recent results - there's been no major change to revenue estimates, but the analysts did make a minor downgrade to their earnings per share forecasts.

Check out our latest analysis for THK

The consensus price target held steady at JP¥4,307, with the analysts seemingly voting that their lower forecast earnings are not expected to lead to a lower stock price in the foreseeable future. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. The most optimistic THK analyst has a price target of JP¥5,310 per share, while the most pessimistic values it at JP¥2,800. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the THK's past performance and to peers in the same industry. We can infer from the latest estimates that forecasts expect a continuation of THK'shistorical trends, as the 5.8% annualised revenue growth to the end of 2026 is roughly in line with the 7.2% annual growth over the past five years. Juxtapose this against our data, which suggests that other companies (with analyst coverage) in the industry are forecast to see their revenues grow 5.0% per year. It's clear that while THK's revenue growth is expected to continue on its current trajectory, it's only expected to grow in line with the industry itself.

The Bottom Line

The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for THK going out to 2027, and you can see them free on our platform here..

Plus, you should also learn about the 2 warning signs we've spotted with THK (including 1 which is potentially serious) .

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.